Last updated: July 23, 2026
Executive summary: Pfizer Inc. sued Macleods Pharmaceuticals, Ltd. in the U.S. District Court for the Northern District of West Virginia (case no. 1:17-cv-00683). The docket and publicly available filings associated with the action indicate a patent dispute tied to a generic filing and the Hatch-Waxman framework, with Pfizer positioning asserted patents against Macleods’ proposed product. The case’s public posture and outcomes on core questions (asserted claims, dispositive rulings, and any settlement terms) cannot be stated accurately from the information provided in this prompt.
What patents did Pfizer assert in Pfizer v. Macleods Pharmaceuticals (1:17-cv-00683)?
Featured answer: The specific Pfizer patents asserted in 1:17-cv-00683 are not identified in the input provided here, so a claim-by-claim or patent-by-patent summary cannot be produced.
Which patent numbers and expiration dates were at issue?
Because the asserted patent list is not included in the prompt, the following cannot be listed:
- Patent numbers asserted by Pfizer
- Legal expiration dates (utility and PTA)
- Any terminal disclaimers
- Whether any patents are formulation, method-of-use, or manufacturing-process patents
Were the asserted patents Orange Book-listed for the reference product?
The drug name and NDA/BLA reference product are not specified in the prompt. Without that, the Orange Book mapping and listed-covering-patent analysis cannot be completed.
How did Macleods respond: what defenses or counterarguments were raised?
Featured answer: The prompt does not include the complaint, answer, or claim construction record, so the specific defenses (non-infringement, invalidity under 35 U.S.C. §§ 102/103/112, unenforceability, lack of standing, or procedural defenses) cannot be enumerated.
What did Macleods argue on infringement?
No product specifics are provided (drug, dosage form, strength, ANDA number). Without that, infringement analysis cannot be done at the limitation level.
What did Macleods argue on validity and enforceability?
No prior art set, claim-scope theories, or inequitable conduct allegations are included in the prompt.
What claims were construed and how did Markman rulings affect the case?
Featured answer: Markman rulings, claim constructions, and their effects on infringement/validity cannot be summarized without the Markman transcript or order content.
Were any claims narrowed by claim construction?
Not determinable from the prompt.
Did the court treat any terms as means-plus-function or apply indefiniteness?
Not determinable from the prompt.
When did Pfizer v. Macleods (1:17-cv-00683) reach key procedural milestones?
Featured answer: The prompt does not provide filing dates beyond the case number and year (2017), nor does it include docket event dates. A timeline cannot be produced without docket-level data.
Key milestones usually tracked in Hatch-Waxman cases
A complete milestone analysis requires, at minimum:
- Complaint filing date
- Service and answer deadlines
- Amended pleadings
- Claim construction schedule and date
- Summary judgment briefing and rulings
- Trial dates or dismissal/settlement dates
- Any PTAB-related stays or co-pending reexamination events
None of these details are in the prompt.
What happened to Pfizer’s case outcome: dismissal, summary judgment, trial, or settlement?
Featured answer: The outcome cannot be stated from the information provided in the prompt.
Was there a consent judgment or stipulated dismissal?
Not determinable from the prompt.
Was a summary judgment entered on infringement or invalidity?
Not determinable from the prompt.
Was there a settlement agreement under Hatch-Waxman triggers?
Not determinable from the prompt.
What is the Paragraph IV landscape for this dispute and how did it shape litigation posture?
Featured answer: The prompt does not identify the ANDA and the patent certifications (Paragraph IV vs. others), so the Paragraph IV framework cannot be analyzed accurately.
Did Macleods certify “PIV” or “non-infringement” for specific listed patents?
Not determinable.
Were there FDA exclusivity or 180-day exclusivity implications mentioned in filings?
Not determinable.
What is the Orange Book status of the reference product in Pfizer v. Macleods (1:17-cv-00683)?
Featured answer: The reference product’s name, NDA number, and Orange Book listings are not provided in the prompt, so the Orange Book status cannot be computed.
Which covering patents were listed and how many are on the Orange Book?
Not determinable.
Are the covering patents formulation, method-of-use, or manufacturing patents?
Not determinable.
Which generic entry risks existed for Macleods if Pfizer’s patents held?
Featured answer: Without the litigated product, dosage form, ANDA status, and asserted patents, the entry risk cannot be evaluated.
What would be the earliest potential generic launch date after exclusivity/patent expiration?
Not determinable.
What injunction scope would have blocked launch?
Not determinable.
How does this case compare with other Pfizer vs. generic litigation outcomes for similar products?
Featured answer: No drug, target reference product, or asserted patent category is provided, so comparison across Pfizer’s comparable disputes cannot be done reliably.
Does this case align with Pfizer’s typical strategy (formulation vs. method-of-use)?
Not determinable.
Did courts in this litigation follow a consistent claim construction approach seen elsewhere?
Not determinable.
Commercial impact: what revenue exposure was at stake for Pfizer from this dispute?
Featured answer: The product, market, and sales figures are not provided in the prompt, so revenue exposure cannot be quantified.
What portion of U.S. sales depended on the litigated patent coverage?
Not determinable.
Did Macleods’ intended launch date coincide with key exclusivity windows?
Not determinable.
Key Takeaways
- Case identity is provided (Pfizer v. Macleods Pharmaceuticals, Ltd., 1:17-cv-00683), but the prompt does not include the factual inputs required to produce a litigation summary that meets patent-analysis standards.
- The asserted patent set, Orange Book mapping, infringement theories, validity defenses, claim construction, and final disposition cannot be stated based on the information in the prompt alone.
- No defensible timeline or settlement posture can be provided without docket event content and the complaint/answer record.
FAQs
- What is the typical claim structure in Pfizer generic-infringement suits filed in 2017 under the Hatch-Waxman framework?
- How do courts weigh method-of-use patents versus formulation patents in ANDA litigation?
- What data points determine whether an injunction would block a generic launch in a Paragraph IV case?
- How do 180-day exclusivity and settlement agreements change the litigation leverage for ANDA applicants?
- What claim-construction outcomes most often narrow Hatch-Waxman infringement theories for generic drugmakers?
References
- No source material was provided in the prompt.
